ABSTRACT
BACKGROUND: Psoriasis is a chronic, immune mediated inflammatory condition that affects a significant amount of the global population. Yet geographic variability in the consequences of psoriasis warrants region-level analyses. OBJECTIVE: The current study contributes to the psoriasis outcomes literature by offering a comprehensive assessment of the humanistic and economic burden in Brazil. METHODS: The 2012 Brazil National Health and Wellness Survey (N=12,000) was used to assess health-related quality of life (Short Form-12, version 2), work productivity, and healthcare resource use associated with experiencing psoriasis vs. no psoriasis, along with varying levels of psoriasis severity. RESULTS: A total of 210 respondents reported diagnosis of psoriasis (N=157, 42, and 11 reporting mild, moderate, and severe psoriasis, respectively). Compared with controls, respondents with psoriasis reported diminished mental component summary scores and health utilities, as well as increased presenteeism, activity impairment, and physician visits over the past six months, adjusting for covariates. Among those with psoriasis, physical health decreased as psoriasis severity increased. Although work productivity and healthcare resource utilization did not differ with psoriasis severity, the high rates of productivity loss (e.g. 45.5% presenteeism in the severe psoriasis group) suggest an economic burden. STUDY LIMITATIONS: Cost analyses were not performed, and cross-sectional patient-reported data limit causal conclusions and may reflect reporting biases. CONCLUSIONS: Nevertheless, these results suggest a significant burden to patients with psoriasis across both humanistic and economic outcomes. The association between psoriasis and mental health aspects and health utilities were particularly strong and exceeded what would be considered clinically meaningful.
Subject(s)
Health Resources/statistics & numerical data , Psoriasis/economics , Psoriasis/physiopathology , Quality of Life , Work Performance/economics , Adult , Analysis of Variance , Brazil , Case-Control Studies , Chronic Disease , Cost of Illness , Cross-Sectional Studies , Disability Evaluation , Efficiency/physiology , Female , Health Surveys , Humans , Linear Models , Male , Middle Aged , Psoriasis/psychology , Quality of Life/psychology , Self Report , Severity of Illness Index , Socioeconomic FactorsABSTRACT
Abstract: Background: Psoriasis is a chronic, immune mediated inflammatory condition that affects a significant amount of the global population. Yet geographic variability in the consequences of psoriasis warrants region-level analyses. Objective: The current study contributes to the psoriasis outcomes literature by offering a comprehensive assessment of the humanistic and economic burden in Brazil. Methods: The 2012 Brazil National Health and Wellness Survey (N=12,000) was used to assess health-related quality of life (Short Form-12, version 2), work productivity, and healthcare resource use associated with experiencing psoriasis vs. no psoriasis, along with varying levels of psoriasis severity. Results: A total of 210 respondents reported diagnosis of psoriasis (N=157, 42, and 11 reporting mild, moderate, and severe psoriasis, respectively). Compared with controls, respondents with psoriasis reported diminished mental component summary scores and health utilities, as well as increased presenteeism, activity impairment, and physician visits over the past six months, adjusting for covariates. Among those with psoriasis, physical health decreased as psoriasis severity increased. Although work productivity and healthcare resource utilization did not differ with psoriasis severity, the high rates of productivity loss (e.g. 45.5% presenteeism in the severe psoriasis group) suggest an economic burden. Study limitations: Cost analyses were not performed, and cross-sectional patient-reported data limit causal conclusions and may reflect reporting biases. Conclusions: Nevertheless, these results suggest a significant burden to patients with psoriasis across both humanistic and economic outcomes. The association between psoriasis and mental health aspects and health utilities were particularly strong and exceeded what would be considered clinically meaningful.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Psoriasis/economics , Psoriasis/physiopathology , Quality of Life/psychology , Work Performance/economics , Health Resources/statistics & numerical data , Psoriasis/psychology , Socioeconomic Factors , Severity of Illness Index , Brazil , Case-Control Studies , Linear Models , Chronic Disease , Cross-Sectional Studies , Analysis of Variance , Health Surveys , Cost of Illness , Disability Evaluation , Efficiency/physiology , Self ReportABSTRACT
RESUMO Objetivo: As doenças causadas pela bactéria Streptococcus pneumoniae (pneumococo) são importantes causas de morbimortalidade no mundo, principalmente em indivíduos nos extremos de idade. O objetivo deste estudo foi avaliar os benefícios e custos incrementais associados à vacina pneumocócica conjugada 13-valente PCV13 (Prevenar® 13), comparada à não utilização de vacina e à utilização de vacina pneumocócica polissacarídica PPSV23 no Sistema de Saúde Suplementar, por meio de uma análise de custo-efetividade. Métodos: Foi realizado um estudo de custo-efetividade utilizando um modelo de Markov que englobou os estados de saúde saudável, doença pneumocócica e morte. Neste estudo foram incluídos dados clínicos de pacientes com doença pneumocócica (bacteremia, meningite, internações por pneumonia e pneumonias ambulatoriais), custos médicos diretos e indiretos, considerando um horizonte de tempo de três anos, com ciclos anuais e uma coorte hipotética de pacientes com 50 anos ou mais. Análises de sensibilidade univariada e probabilística também foram realizadas. Resultados: A utilização da vacina PCV13 se mostrou dominante em relação às demais estratégias nos pacientes com risco baixo, moderado e alto. A análise de sensibilidade probabilística indica que a chance de PCV13 ser a estratégia mais custo-efetiva é de 90%, quando um limiar de R$ 12.000 para cada ano de vida ganho é definido. Conclusões: Foi possível observar que a utilização da vacina PCV13 para a prevenção de doenças pneumocócicas em adultos com 50 anos ou mais, considerando o desfecho clínico "anos de vida salvos", pode ser a estratégia mais eficiente quando comparada à não vacinação ou à utilização da vacina PPSV23.
Diseases caused by the bacteria Streptococcus pneumoniae are important sources of morbidity and mortality around the world, specially in regard to elderly people. We sought to assess costs and benefits inherent to 13-valent pneumococcal conjugate vaccine (PCV13, Prevenar® 13) compared to pneumococcal polysaccharide vacine (PPSV23) and the policy of does providing vaccine in the perspective of Brazilian Private Health System. Methods: A cost-effectiveness analysis model was performed by means of a Markov modelling which comprised the health states healthy, pneumococcal disease and death. In this study were included clinical data of patients with pneumococcal disease (bacteremia, meningitis, hospitalization due to pneumonia and community acquired pneumonia) and direct and indirect medical costs. A three year time horizon and an annual cycle were set. The hypothetic cohort corresponds to patients aging 50 years or more. One-way and probabilistic sensitivity analyses were performed. Results: PCV13 is dominant over PPSV23 and non- -vaccination policy in low- moderate- and high-risk patients. Probabilistic analysis shows that PCV13 has a probability of being 90% more cost-effective when a threshold of BRL 12.000 is defined for each incremental life-year gained. Conclusions: Considering the outcome life-years gained PCV13 is the strategy that most promote value for money in patients aging 50 years or more, in the Brazilian Private Health System.
Subject(s)
Humans , Pneumococcal Infections , Health Evaluation , Cost-Benefit Analysis , Pneumococcal VaccinesABSTRACT
ABSTRACT BACKGROUND AND OBJECTIVES: Adequate postoperative pain and renal colic control is critical for patients' recovery and to decrease hospitalization costs and the use of resources. So, this study aimed at evaluating hospitalization time of patients treated with parecoxib sodium versus other non-steroid anti-inflammatory drugs to manage postoperative pain of appendectomy or fractures and renal colic. METHODS: This is a retrospective data analysis of Brazilian private hospitals medical bills, including patients treated with non-steroid anti-inflammatory drugs to decrease post-appendectomy pain (n=1618), post orthopedic fracture pain (n=2858 and renal colic (n=6555), between January and June 2014. Mean hospitalization time was evaluated according to each group of drugs. Mean difference among groups was calculated by the Kruskal-Wallis method. RESULTS: Mean hospitalization time for patients submitted to appendectomy was 1.95 days with parecoxib versus 2.20 with other non-steroid anti-inflammatory drugs (p= 0.006). For patients submitted to orthopedic fracture surgery, mean time was 1.75 days with parecoxib versus 1.93 days with other anti-inflammatory drugs (p=0.008). Parecoxib has also significantly decreased hospitalization time for renal colic as compared to other drugs (25.2h versus 32.9h; p<0.001). CONCLUSION: Parecoxib sodium has provided shorter hospitalization time with possible decrease in use of resources and costs and should be considered a choice for such painful conditions.
RESUMO JUSTIFICATIVA E OBJETIVOS: O controle adequado da dor pós-operatória e cólica renal é fundamental para a recuperação do paciente e redução de custos relacionados à hospitalização e utilização de recursos. Assim, o objetivo deste estudo foi avaliar o tempo de hospitalização entre pacientes tratados com parecoxibe sódico versus outros fármacos anti-inflamatórios não esteroides, no manuseio da dor pós-operatória associada à apendicectomia ou fraturas e cólica renal. MÉTODOS: Uma análise retrospectiva de dados de contas médicas de hospitais privados no Brasil foi realizada, incluindo pacientes tratados com anti-inflamatório não esteroide para redução da dor pós-apendicectomia (n=1.618), dor pós-fratura ortopédica (n=2.858) e cólica renal (n=6.555), entre janeiro e junho de 2014. O período médio de internação foi avaliado de acordo com cada grupo de fármacos. A diferença média entre os grupos foi avaliada utilizando o método de Kruskal-Wallis. RESULTADOS: O tempo médio de permanência hospitalar para pacientes submetidos à apendicectomia foi de 1,95 dias com parecoxibe versus 2,20 com outros anti-inflamatórios não esteroides (p = 0,006). Para pacientes submetidos a cirurgias de fraturas ortopédicas, o tempo médio foi de 1,75 dias com parecoxibe versus 1,93 dias para outros anti-inflamatórios (p=0,008). Parecoxibe também apresentou redução significativa no tempo de internação hospitalar para cólica renal em comparação com outros fármacos (25,2h versus 32,9h; p<0,001). CONCLUSÃO: Parecoxibe sódico demonstrou menor tempo de permanência hospitalar com possível redução na utilização de recursos e custos, devendo ser considerado como uma escolha para estas condições dolorosas.
ABSTRACT
BACKGROUND: Acute coronary syndrome (ACS) is defined as a "group of clinical symptoms compatible with acute myocardial ischemia", representing the leading cause of death worldwide, with a high clinical and financial impact. In this sense, the development of economic studies assessing the costs related to the treatment of ACS should be considered. OBJECTIVE: To evaluate costs and length of hospital stay between groups of patients treated for ACS undergoing angioplasty with or without stent implantation (stent+ / stent-), coronary artery bypass surgery (CABG) and treated only clinically (Clinical) from the perspective of the Brazilian Supplementary Health System (SHS). METHODS: A retrospective analysis of medical claims of beneficiaries of health plans was performed considering hospitalization costs and length of hospital stay for management of patients undergoing different types of treatment for ACS, between Jan/2010 and Jun/2012. RESULTS: The average costs per patient were R$ 18,261.77, R$ 30,611.07, R$ 37,454.94 and R$ 40,883.37 in the following groups: Clinical, stent-, stent+ and CABG, respectively. The average costs per day of hospitalization were R$ 1,987.03, R$ 4,024.72, R$ 6,033.40 and R$ 2,663.82, respectively. The average results for length of stay were 9.19 days, 7.61 days, 6.19 days and 15.20 days in these same groups. The differences were significant between all groups except Clinical and stent- and between stent + and CABG groups for cost analysis. CONCLUSION: Hospitalization costs of SCA are high in the Brazilian SHS, being significantly higher when interventional procedures are required.
Subject(s)
Acute Coronary Syndrome/therapy , Angioplasty, Balloon, Coronary/economics , Coronary Artery Bypass/economics , Health Expenditures , Health Maintenance Organizations/economics , Acute Coronary Syndrome/economics , Aged , Brazil , Female , Hospitalization/economics , Humans , Male , Middle Aged , Retrospective Studies , Statistics, Nonparametric , Stents/economics , Time FactorsABSTRACT
AbstractBackground:Acute coronary syndrome (ACS) is defined as a “group of clinical symptoms compatible with acute myocardial ischemia”, representing the leading cause of death worldwide, with a high clinical and financial impact. In this sense, the development of economic studies assessing the costs related to the treatment of ACS should be considered.Objective:To evaluate costs and length of hospital stay between groups of patients treated for ACS undergoing angioplasty with or without stent implantation (stent+ / stent-), coronary artery bypass surgery (CABG) and treated only clinically (Clinical) from the perspective of the Brazilian Supplementary Health System (SHS).Methods:A retrospective analysis of medical claims of beneficiaries of health plans was performed considering hospitalization costs and length of hospital stay for management of patients undergoing different types of treatment for ACS, between Jan/2010 and Jun/2012.Results:The average costs per patient were R$ 18,261.77, R$ 30,611.07, R$ 37,454.94 and R$ 40,883.37 in the following groups: Clinical, stent-, stent+ and CABG, respectively. The average costs per day of hospitalization were R$ 1,987.03, R$ 4,024.72, R$ 6,033.40 and R$ 2,663.82, respectively. The average results for length of stay were 9.19 days, 7.61 days, 6.19 days and 15.20 days in these same groups. The differences were significant between all groups except Clinical and stent- and between stent + and CABG groups for cost analysis.Conclusion:Hospitalization costs of SCA are high in the Brazilian SHS, being significantly higher when interventional procedures are required.
Fundamento:Síndrome coronariana aguda (SCA) é definida como um “grupo de sintomas clínicos compatíveis com isquemia miocárdica aguda”, representando a principal causa de óbito no mundo, com elevado impacto clínico e financeiro. Nesse sentido, o desenvolvimento de estudos econômicos que avaliem os custos despendidos no tratamento da SCA deve ser considerado.Objetivo:Avaliar custos e tempo de internação hospitalar entre grupos de pacientes que trataram SCA, submetidos a procedimentos de angioplastia com ou sem implante de stent (stent+ / stent-), revascularização (Revasc) e tratados apenas clinicamente (Clínico), sob a perspectiva do sistema de saúde suplementar (SSS) brasileiro.Métodos:Realizou-se uma análise retrospectiva de contas médicas de beneficiários de planos de saúde considerando dados de custos de internação e tempo de permanência hospitalar para o manejo de pacientes submetidos a diferentes tipos de tratamento para SCA, no período entre 1/2010 e 6/2012.Resultados:Os custos médios por paciente foram de R$ 18.261,77, R$ 30.611,07, R$ 37.454,94 e R$ 40.883,37 nos grupos Clínico, stent-, stent+ e Revasc, respectivamente. Os custos médios por dia de internação foram de R$ 1.987,03, R$ 4.024,72, R$ 6.033,40 e R$ 2.663,82, respectivamente. Os tempos médios de internação foram de 9,19 dias, 7,61 dias, 6,19 dias e 15,20 dias nesses mesmos grupos. As diferenças foram estatisticamente significativas entre todos os grupos, exceto Clínico e stent- e entre os grupos stent + e Revasc, para a análise de custos.Conclusão:O custo hospitalar da SCA é elevado no SSS brasileiro e significativamente mais alto quando há a necessidade da realização de procedimentos intervencionistas.